Navigation Links
New Treatment Mooted For Blood Pressure

InterCure, Ltd. has announced that it will be publishing a peer-reviewed clinical overview to test how efficient device-guided breathing is. RESPeRATE, a over-the-counter// therapeutic device that is approved by FDA could be a viable option to treat hypertension, the study says.

The article, published in the General Medicine Journal (http://www.medscape.com/viewarticle/539099) of Medscape (NASDAQ:WBMD), is authored by William J. Elliott, MD, PhD, professor of Preventive Medicine, Internal Medicine and Pharmacology at Rush Medical College, Ill., and Joseph L. Izzo, Jr., MD, professor of medicine and vice chair of Medical Research at the University of Buffalo, N.Y.

The article confirms the body of evidence from seven published clinical studies concluding that routine use of RESPeRATE, either alone or as an adjunctive treatment with lifestyle modifications or prescription drugs, significantly lowered blood pressure with no adverse side effects. The study also reviews the physiological mechanism of action of device-guided breathing.

A summary of the results of the seven studies shows an average all-day reduction of 14/8 mm Hg within four to six weeks of commencement of 15-minute-daily treatments with RESPeRATE. The reduction in blood pressure was consistent between studies, whether measurements were taken in the home, 24-hour ambulatory setting or physician's office. Larger blood pressure reductions were seen in older individuals and those with higher baseline readings, regardless of whether they were also being treated with prescription antihypertensive medications.

The authors summarize the patient populations for whom device-guided breathing appears to be beneficial: (1) prehypertensives and white-coat or labile hypertensives who might benefit from reducing stress and sympathetic activity; (2) patients with isolated systolic hypertension; and (3) patients with resistant hypertension (uncontrolled blood pressure despite
'"/>




Page: 1 2

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Treatment Mooted For Blood Pressure

Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10The Forsyth Institute receives the William J Gies Award for outstanding achievement 62358 1The Forsyth Institute receives the William J Gies Award for outstanding achievement 62358 2Are the effects of pornography negligible 3F 62355 1Are the effects of pornography negligible 3F 62355 2Tumor attacking virus strikes with one two punch 10941 1Tumor attacking virus strikes with one two punch 10941 2